Mulpleta approved in China to treatthrombocytopenia in adult patients with chronic liver disease
Shionogi announced that its Chinese license partner Eddingpharm has won regulatory approval for its thrombopoietin receptor agonist Mulpleta (lusutrombopag) in China
The drug was approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an elective invasive procedure.
Originated by Shionogi, Mulpleta is a small molecule agonist of the human thrombopoietin receptor that increases platelet counts. It has already been approved in Japan, the US, and Europe as an alternative therapy to platelet transfusion for CLD patients complicated by thrombocytopenia. In China, CLD affects roughly 13.6 million adults.
The Osaka drug maker inked a license pact with Eddingpharm to out-license the exclusive marketing rights of Mulpleta in mainland China, Hong Kong, and Macau. Under this deal, Shionogi will supply the product to Eddingpharm and receive an upfront payment as well as milestones according to post-launch sales periods.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins